Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Hot off the press.
- Published a day after American Society of Clinical Oncology (ASCO) annual meeting #ASCO26
- Pleased to share our comment in Nature Reviews Cancer Journal at Nature Portfolio
- ‘Mutation-centric kinase drug repurposing for rare cancers’
- Rare cancers remain underserved by precision oncology.
- We propose that systematic, variant-level pharmacological mapping of approved kinase inhibitors can transform this gap into an opportunity for scalable drug repurposing
Pleasure to collaborate on this paper led by Taran Gujral et al Fred Hutch.”
Title: Mutation-centric kinase drug repurposing for rare cancers
Authors: Marina Chan, Haiching Ma, Vivek Subbiah, Taranjit S. Gujral
Other articles featuring Vivek Subbiah on OncoDaily.